HeartBeam, Inc. (BEAT)
| Market Cap | 60.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.62M |
| Shares Out | 40.12M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 351,946 |
| Open | 1.540 |
| Previous Close | 1.550 |
| Day's Range | 1.480 - 1.555 |
| 52-Week Range | 0.540 - 4.000 |
| Beta | -0.81 |
| Analysts | Strong Buy |
| Price Target | 6.75 (+347.02%) |
| Earnings Date | Mar 13, 2026 |
About BEAT
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for BEAT stock is "Strong Buy." The 12-month stock price target is $6.75, which is an increase of 347.02% from the latest price.
News
HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer.
HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference.
Why Is Micro Cap HeartBeam Stock Surging On Wednesday?
HeartBeam, Inc.'s (NASDAQ: BEAT) stock is trading higher on Monday, with a session volume of 193.38 million compared to the average volume of 2.191 million as per data from Benzinga Pro.
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment.
HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application.
HeartBeam, Inc. (BEAT) Q3 2025 Earnings Call Transcript
HeartBeam, Inc. ( BEAT) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Robert Eno - CEO, Chief Business Officer & Director Timothy Cruickshank - Chief Financial Officer Conf...
HeartBeam Reports Third Quarter 2025 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2025 Results.
HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time.
HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere.
HeartBeam's Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam's Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias.
HeartBeam to Participate at Upcoming Industry and Investor Conferences, September 4-10, 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Participate at Upcoming Industry and Investor Conferences, September 4-10, 2025.
HeartBeam, Inc. (BEAT) Q2 2025 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Ian Scargill - Corporate Participant Robert P. Eno - CEO, Chief Business Officer & Direc...
HeartBeam Reports Second Quarter 2025 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2025 Results.
HeartBeam to Host Second Quarter 2025 Results Conference Call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2025 Results Conference Call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern Time.
HeartBeam Wins Industry Innovation Award for Advancing Remote Cardiac Care With Groundbreaking ECG Technology
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Wins Industry Innovation Award for Advancing Remote Cardiac Care with Groundbreaking ECG Technology.
HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025.
HeartBeam, Inc. (BEAT) Q1 2025 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Rob Eno - CEO Tim Cruickshank - CFO Larry Holub - IR, MZ Group Conference Call Participants...
HeartBeam Reports First Quarter 2025 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2025 Results.
HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio.
HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth.
HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time.
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology.
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation
SANTA CLARA, Calif. & NEW YORK--(BUSINESS WIRE)--HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation.
HeartBeam, Inc. (BEAT) Q4 2024 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2024 Results Conference Call March 13, 2025 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Tim Cruickshank - Chief Financial Officer Operator Greet...
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Fourth Quarter and Full Year 2024 Results.